JP3647898B2 - Sodium bicarbonate dialysis agent and method for producing the same - Google Patents
Sodium bicarbonate dialysis agent and method for producing the same Download PDFInfo
- Publication number
- JP3647898B2 JP3647898B2 JP16994594A JP16994594A JP3647898B2 JP 3647898 B2 JP3647898 B2 JP 3647898B2 JP 16994594 A JP16994594 A JP 16994594A JP 16994594 A JP16994594 A JP 16994594A JP 3647898 B2 JP3647898 B2 JP 3647898B2
- Authority
- JP
- Japan
- Prior art keywords
- layer
- acid
- bicarbonate
- organic acid
- dialysis agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 title claims description 56
- 238000000502 dialysis Methods 0.000 title claims description 32
- 239000003795 chemical substances by application Substances 0.000 title claims description 29
- 235000017557 sodium bicarbonate Nutrition 0.000 title claims description 28
- 229910000030 sodium bicarbonate Inorganic materials 0.000 title claims description 28
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- 150000007524 organic acids Chemical class 0.000 claims description 33
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 31
- 159000000007 calcium salts Chemical group 0.000 claims description 28
- 159000000003 magnesium salts Chemical class 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 235000002639 sodium chloride Nutrition 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 7
- 239000002274 desiccant Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000843 powder Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000010030 laminating Methods 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 235000011147 magnesium chloride Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007784 solid electrolyte Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、炭酸水素イオンを含有する透析液、すなわち重曹透析液を調製するための積層製剤に関する。
【0002】
【従来の技術】
従来、血液透析を行う場合、以下に示すような組成の重曹透析液が用いられている。
Na+ 120〜150 mEq/l
K+ 0.5〜3.0 mEq/l
Ca++ 1.5〜4.5 mEq/l
Mg++ 0〜2.0 mEq/l
Cl- 90〜135 mEq/l
HCO3 - 20〜 35 mEq/l
CH3CO2 - 5〜 10 mEq/l
ブドウ糖 0〜2.5 g/l
しかし、このような組成の透析液は、一人一回の透析に約350リットルもの大量が使用され、しかも製剤的に不安定なことから、使用直前に調製せざるを得ず、煩雑な作業を要するものであった。
【0003】
そこで前記作業を軽減するものとして、一人一回分の包装単位で、必要成分中の炭酸水素ナトリウムを別にした濃厚原液(約11リットル)が市販されるようになった。しかし、組成中の炭酸水素ナトリウムがカルシウム塩やマグネシウム塩と反応して炭酸塩の沈澱を生じるため、現在使用されている透析液は、原液を一液にすることができず、二液に分けて製品化されている。そのため、運搬、保管場所、取扱い等において十分改良されたとは言えず、その後も種々の提案がなされている。
このような点に鑑み、透析用剤を粉末化しようとする試みがなされている。例えば、特開平3−74331号公報には透析液に必要な成分を、カルシウム成分を含み重曹を含まない群からなる造粒物と、重曹を含みカルシウム成分を含まない群からなる造粒物との混合物について開示されている。これは、所定量の透析用剤を単に水に溶解するだけで透析液の調製ができるようにしたものであるが、pH調整剤として用いられている酢酸が、カルシウム塩、マグネシウム塩及び重炭酸塩と同時に溶解するため、不溶性の沈澱が生じたり、炭酸ガスが発生してpHが高くなり易いという欠点がある。また、長期保存中にも反応が進行して、凝集が生じたり、含量の低下を引き起こす等の問題を有している。一方、特開平2−311418号公報には透析用固体電解質及び液体酸よりなる粉末状組成物と、炭酸水素ナトリウム及びブドウ糖の粉末状組成物と二つの組成物よりなる粉末状透析用製剤が開示されている。また、特開平4−257522号公報には透析用電解質成分のうち重曹以外の成分から選ばれた1種以上からなる群と、重曹を主成分とする群からなる二剤の造粒物、特開平5−70357号公報には、透析用電解質、ブドウ糖及び重曹の三成分を別々の顆粒状組成物とした透析用剤が開示されている。しかし、これらはいずれも二剤あるいは三剤に分けて製造されていることから取り扱いについての問題点は何ら解決されていない。
【0004】
【発明が解決しようとする課題】
本発明の課題は、長期保存に対して安定性に優れ、しかも使用時に各成分が順次溶解することにより沈澱の析出を防止でき、かつ容易に調製できる重曹透析用剤を提供することにある。
【0005】
【課題を解決するための手段】
本発明者らは、透析用剤に必要な各電解質及びブドウ糖の安定性及び吸湿性について考慮しながら、pH調整剤も含めた安定な積層製剤を提供することについて鋭意研究した。その結果、核に塩化ナトリウムを用いて、カルシウム塩又は/及びマグネシウム塩を含み有機酸及び重炭酸塩を含まない群、有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩を含まない群及び重炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸を含まない群を積層するとき、カルシウム塩、マグネシウム塩、有機酸及び重炭酸塩以外の成分から選ばれた群を介して順次積層することにより前記課題が解決できることを見い出し、本発明を完成した。
【0006】
すなわち、本発明は、電解質、有機酸及びブドウ糖を含有する透析用剤であって、前記有機酸が酢酸、乳酸、クエン酸、酒石酸、マレイン酸、オキサロ酢酸、イソクエン酸及びリンゴ酸からなる群から選ばれた一種又は二種以上であり、積層製剤が、核、第一層、第二層及び第三層の多層構造を有し、核が塩化ナトリウムである透析用剤において、第一層はカルシウム塩又は/及びマグネシウム塩を含み有機酸及び重炭酸塩を含まない層であり、第二層は二層以上に分けて積層され、かつ有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩を含まない層であり、第三層は重炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸を含まない層であることを特徴とする重曹透析用剤である。この積層製剤は、炭酸ガス気流中防湿を施した気密容器内に充填し、乾燥剤と共に収納される。
【0007】
本発明の重曹透析用剤に含まれる成分の好ましい配合範囲を、透析液調製後の組成範囲で示せば下記の如くであり、そのpHは7.0〜8.0、より好ましくは7.2〜7.6である。
Na+ 120〜150 mEq/l
K+ 0〜 4 mEq/l
Ca++ 1〜 6 mEq/l
Mg++ 0〜 2 mEq/l
Cl- 90〜135 mEq/l
CH3CO2 - 2〜 15 mEq/l
HCO3- 10〜 40 mEq/l
ブドウ糖 0〜 10 g/l
【0008】
本発明の重曹透析用剤の製造に当たり、化合物を選択し配合割合を設定する場合は、例えば上記に基づいて各成分の濃度を設定し、各成分を供給できる化合物の組合せにより逆算すればよい。
【0009】
本発明に使用される電解質は、薬理学的に許容されるものでなければならない。例えば、炭酸水素ナトリウム、炭酸水素カリウム、塩化ナトリウム、塩化カリウム、塩化カルシウム、塩化マグネシウム、酢酸ナトリウム、酢酸カリウム、グルコン酸カルシウム等をあげることができる。
本発明を構成する積層製剤は、上記のような電解質と共に、血中に含まれるその他の成分、例えばブドウ糖を含むことができる。
【0010】
前記積層製剤は、カルシウム塩及び/又はマグネシウム塩を含み有機酸及び重炭酸塩を含まない群(第一層)、有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩を含まない群(第二層)及び重炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸を含まない群(第三層)が重要である。すなわち、カルシウム塩及び/又はマグネシウム塩を含み有機酸及び重炭酸塩を含まない群と重炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸を含まない群をカルシウム塩、マグネシウム塩、有機酸及び重炭酸塩以外の成分から選ばれた群を介して接触しないように積層することにより、カルシウム塩及びマグネシウム塩が重炭酸塩と反応することを防止することができる。また有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩を含まない群と重炭酸塩を含みカルシウム塩、マグネシウム塩及び有機酸を含まない群をカルシウム塩、マグネシウム塩、有機酸及び重炭酸塩以外の成分から選ばれた群を介して接触しないように積層することにより重炭酸塩と有機酸の反応を防ぐことができる。すなわち、透析液の調製の際に、積層製剤の外層から蒸留水に順次溶解して、pHが中性から微アルカリに調整されるため、炭酸ガスの発生を、またカルシウム塩やマグネシウム塩が最後に溶解するため、炭酸カルシウム及び炭酸マグネシウムの沈澱生成を防ぐことができる。また所望により積層順序を変えてもよいし、前記第一層、第二層及び第三層は、さらに二層以上の多層より構成されていてもよい。
【0011】
以下に本発明の積層操作を述べる。本発明の製造方法は、核に順次積層する工程からなり、一般的に使用される造粒及びコーティング装置によって実施される。
例えば、使用する群をカルシウム塩及び/又はマグネシウム塩を含み有機酸及び重炭酸塩を含まない群、有機酸を含みカルシウム塩、マグネシウム塩及び重炭酸塩を含まない群、重炭酸塩含みカルシウム塩、マグネシウム塩及び有機酸を含まない群及びカルシウム塩、マグネシウム塩、有機酸及び重炭酸塩以外の成分から選ばれた群に分け、各群の成分を適宜サンプルミル(不二パウダル社製)等の粉砕機で微粉化する。次に核の塩化ナトリウム結晶粒子を遠心流動型コーティング造粒装置に入れ、回転させ、結合剤として適量のブドウ糖溶液を噴霧しながら前記微粉末を順次粉末添加することによって球形の積層製剤が得られる。
【0012】
本発明の重曹透析用剤の剤型としては、核の表面に、第一層から順次積層される球形の積層製剤が好ましい。
【0013】
前記有機酸としては、例えば酢酸、乳酸、クエン酸、酒石酸、マレイン酸、オキサロ酢酸、イソクエン酸、リンゴ酸等をあげることができ、とりわけクエン酸が好ましい。酸の使用量は、透析液のpHが7.0〜8.0の範囲になるように加えるのが好ましい。より好ましい範囲はpH7.2〜7.6である。これらの有機酸は1種のみならず2種以上を混合して用いることもできる。
【0014】
本発明の積層製剤の製造方法に用いられる結合剤は、成分中のブドウ糖が使用されているため安全であり、また結合力が強いので高強度で粉状化しにくい積層製剤を得ることができる。ブドウ糖は溶媒に適宜溶解して用いられるが、好ましい濃度としては0.5〜55W/W%が適当である。溶媒としては、製剤化に用いられ、ブドウ糖が溶解するものであれば特に限定されないが、好ましくは水あるいは水とエタノールの混合溶媒である。
【0015】
本発明の重曹透析用剤の保存容器に用いられる素材としては、実質的に防湿性及びガス非透過性のものであれば特に限定されないが、例えば、ポリエチレン、ポリプロピレン、ポリ塩化ビニル等あるいはアルミニウムの如き金属箔、ナイロン、セロファン等を、適宜二層ないし多層に積層したラミネートフィルムがあげられる。
【0016】
前記のような包装形態の気密性容器に、炭酸ガス気流中乾燥剤と共に密封すると、より安定性を向上させることができるので好都合である。乾燥剤としてはシリカゲル、塩化カルシウム、炭酸カルシウム等が用いられる。
【0017】
【作用】
このようにして得られる重曹透析用剤は、有機酸と重炭酸塩を接触しないように積層しているので成分間の反応を防ぐことができる。また、透析液を調製する際は、特にpH調整を行わなくても重炭酸塩から順次溶解して、液のpHが中性から微アルカリ性に調整され、最後にカルシウム塩及びマグネシウム塩が溶解するので、炭酸塩の沈澱が生成しない。
【0018】
【実施例】
以下、実施例及び試験例に基づいて、本発明をさらに詳細に説明するが、本発明はこれらの実施例に限定されるものではない。
〔実施例1〕
塩化マグネシウム17.9g、塩化カルシウム38.7g及び塩化カリウム26.1gを万能攪拌機(品川工業製、SD-02型)で攪拌し、サンプルミル(不二パウダル製、粉砕機KIIW-1)で粉砕して第一層の微粉末を得た。同様にして、クエン酸35g、塩化ナトリウム105gを混合、粉砕して第二層(内層)の微粉末を得た。ブドウ糖91.0g、酢酸ナトリウム85.9g及び塩化ナトリウム100.9gを前記同様の操作を行い第二層(中間層)の微粉末を得た。第二層(外層)として塩化ナトリウム157.5gを粉砕し微粉末を得た。さらに第三層として炭酸水素ナトリウム441gを粉砕し微粉末を得た。次に粒子径350〜500μmの塩化ナトリウム700gを遠心流動造粒コーチング装置(フロイント産業社製、CF-360S型)に入れ、回転させ(回転数200rpm)、ブドウ糖溶液を噴霧しながら第一層、第二層(内層)、第二層(中間層)、第二層(外層)及び第三層の順に微粉末を添加し、球形の積層製剤を得た。得られた積層製剤を常法により乾燥し目的の透析用剤を得た。
【0019】
〔実施例2〕
塩化マグネシウム17.9g、塩化カルシウム38.7g及び塩化カリウム26.1gを万能攪拌機で攪拌し、サンプルミルで粉砕して第一層の微粉末を得た。同様にして、クエン酸35g、塩化ナトリウム105gを混合、粉砕して第二層(内層)の微粉末を得た。ブドウ糖91.0g及び塩化ナトリウム100.9gを前記同様の操作を行い第二層(中間層)の微粉末を得た。第二層(外層)として酢酸ナトリウム85.9g及び塩化ナトリウム157.5gを粉砕し微粉末を得た。さらに第三層として炭酸水素ナトリウム441gを粉砕し微粉末を得た。次に粒子径350〜500μmの塩化ナトリウム700gを遠心流動造粒コーチング装置(フロイント産業社製、CF-360S型)に入れ、回転させ(回転数200rpm)、ブドウ糖溶液を噴霧しながら第一層、第二層(内層)、第二層(中間層)、第二層(外層)及び第三層の順に微粉末を添加し、球形の積層製剤を得た。得られた積層製剤を常法により乾燥し、目的の透析用剤を得た。
【0020】
〔実施例3〕
転動流動造粒乾燥装置(マルチプレックス、MP-01型、パウレックス社製)に、粒子径350〜500μmの塩化ナトリウム700gを入れ、塩化マグネシウム17.9g、塩化カルシウム38.7g及び塩化カリウム26.1g精製水193gに溶解した第一層の液をコーティングした。次に、クエン酸35g、塩化ナトリウム105gを326.7gの精製水に溶解した第二層(内層)の液をコーティングし、順次、ブドウ糖148.75g、酢酸ナトリウム85.9g及び塩化ナトリウム100.9gを精精水4139.1gに溶解した第二層(中間層)の液、塩化ナトリウム157.5gを水472.5gに溶解した第二層(外層)の液をコーティングした。上記積層された造粒物700gを遠心流動造粒コーチング装置(フロイント産業社製、CF-360S型)に入れ、回転させ(回転数200rpm)、ブドウ糖溶液を噴霧しながらサンプルミルで粉砕した第三層の炭酸水素ナトリウムの微粉末214g添加し、球形の積層製剤を得た。得られた積層製剤を常法により乾燥し目的の透析用剤を得た。
【0021】
〔実施例4〕
塩化マグネシウム17.9g、塩化カルシウム38.7g及び塩化カリウム26.1gを万能攪拌機(品川工業製、SD-02型)で攪拌し、サンプルミル(不二パウダル製、粉砕機KIIW-1)で粉砕して第一層の微粉末を得た。同様にして、クエン酸35g、塩化ナトリウム105gを混合、粉砕して第二層(内層)の微粉末を得た。ブドウ糖91.0g、酢酸ナトリウム85.9g及び塩化ナトリウム258.4gを前記同様の操作を行い第二層(外層)の微粉末を得た。さらに第三層として炭酸水素ナトリウム441gを粉砕し微粉末を得た。次に粒子径350〜500μmの塩化ナトリウム700gを遠心流動造粒コーチング装置(フロイント産業社製、CF-360S型)に入れ、回転させ(回転数200rpm)、ブドウ糖溶液を噴霧しながら第一層、第二層(内層)、第二層(外層)及び第三層の順に微粉末を添加し、球形の積層製剤を得た。得られた積層製剤を常法により乾燥し目的の透析用剤を得た。
【0022】
〔試験例1〕安定性試験
実施例1で得られた透析用剤を、1)乾燥剤及び炭酸ガス置換なし、2)乾燥剤としてシリカゲルを収納、3)容器を炭酸ガス置換、4)乾燥剤としてシリカゲルを収納し、かつ容器を炭酸ガス置換の4条件で、それぞれガラス瓶に入れ、密封して40℃に保存した後、色差(△E)、凝集の有無、溶解後の炭酸水素イオン濃度及びpHを測定した。
なお、色差は標準白板をを対照とし、色差計(日本電色工業社製、Σ80型)を用いて測定した。炭酸水素イオン及びpHは、試料10.76gを精製水に溶かして1000mlとし、それぞれイオンクロマトグラフィー(横川電機社製、IC-500S型)及びpHメータ(堀場製作所製、F-16型)を用いて測定した。
それらの結果を、表1に示した。
【0023】
【表1】
【0024】
以上の結果から、シリカゲルと共に収納することにより着色が抑制され、炭酸ガスで置換することにより炭酸水素イオン含量が安定に維持されることが明らかとなった。また溶解に際し、いずれも数分以内に、速やかに溶解した。
【0025】
【発明の効果】
本発明の重曹透析用剤は、前記のように多層に積層されているので、長期間の安定性に優れている。また、一剤中に必要な成分をすべて含んでいることから取扱いが容易である。[0001]
[Industrial application fields]
The present invention relates to a layered preparation for preparing a dialysate containing bicarbonate ions, that is, a sodium bicarbonate dialysate.
[0002]
[Prior art]
Conventionally, when hemodialysis is performed, a sodium bicarbonate dialysis solution having the following composition is used.
Na + 120-150 mEq / l
K + 0.5-3.0 mEq / l
Ca ++ 1.5-4.5 mEq / l
Mg ++ 0-2.0 mEq / l
Cl - 90-135 mEq / l
HCO 3 - 20~ 35 mEq / l
CH 3 CO 2 - 5~ 10 mEq / l
Glucose 0-2.5 g / l
However, the dialysate having such a composition is used in a large amount of about 350 liters per dialysis per person, and because it is unstable in terms of formulation, it must be prepared immediately before use, and complicated work is required. It was necessary.
[0003]
In order to alleviate the above work, a concentrated stock solution (about 11 liters) in which the sodium bicarbonate contained in the necessary components is separated from the packaging unit for one person is now on the market. However, since sodium bicarbonate in the composition reacts with calcium salt and magnesium salt to cause precipitation of carbonate, currently used dialysate cannot be made into one solution, and it is divided into two solutions. Have been commercialized. Therefore, it cannot be said that it has been sufficiently improved in transportation, storage location, handling, etc., and various proposals have been made thereafter.
In view of these points, attempts have been made to powder dialysis agents. For example, Japanese Patent Laid-Open No. 3-74331 discloses a component required for a dialysis solution, a granulated product composed of a group containing a calcium component and not containing sodium bicarbonate, and a granulated product consisting of a group containing sodium bicarbonate and not containing a calcium component; Is disclosed. In this method, a dialysate can be prepared by simply dissolving a predetermined amount of a dialysis agent in water. However, acetic acid used as a pH adjuster is a calcium salt, magnesium salt and bicarbonate. Since it dissolves at the same time as the salt, there are disadvantages that insoluble precipitation occurs and carbon dioxide gas is generated, resulting in a high pH. In addition, the reaction proceeds during long-term storage, causing problems such as aggregation and a decrease in content. On the other hand, JP-A-2-31418 discloses a powdered composition comprising a solid electrolyte for dialysis and a liquid acid, a powdered composition of sodium bicarbonate and glucose, and a powdery composition for dialysis comprising two compositions. Has been. JP-A-4-257522 discloses a two-part granulated product comprising a group consisting of one or more selected from components other than baking soda among dialysis electrolyte components, and a group consisting mainly of sodium bicarbonate. Japanese Laid-Open Patent Publication No. 5-70357 discloses a dialysis agent in which three components of a dialysis electrolyte, glucose and baking soda are used as separate granular compositions. However, since these are manufactured separately in two or three parts, the problem of handling has not been solved at all.
[0004]
[Problems to be solved by the invention]
An object of the present invention is to provide a sodium bicarbonate dialysis agent that is excellent in stability with respect to long-term storage and that can be easily prepared by preventing the precipitation of precipitates by dissolving each component sequentially during use.
[0005]
[Means for Solving the Problems]
The present inventors diligently studied to provide a stable laminated preparation including a pH adjuster while considering the stability and hygroscopicity of each electrolyte and glucose required for the dialysis agent. As a result, using sodium chloride as the nucleus, the group containing calcium salt and / or magnesium salt and not containing organic acid and bicarbonate, the group containing organic acid and not containing calcium salt, magnesium salt and bicarbonate, and When laminating a group containing carbonate and not containing calcium salt, magnesium salt and organic acid, by laminating sequentially through a group selected from components other than calcium salt, magnesium salt, organic acid and bicarbonate The present invention has been completed by finding out that the problem can be solved.
[0006]
That is, the present invention is a dialysis agent comprising an electrolyte, an organic acid and glucose, wherein the organic acid is selected from the group consisting of acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid. In the dialysis agent, which is one or more selected, the layered preparation has a multilayer structure of a core, a first layer, a second layer, and a third layer, and the core is sodium chloride, the first layer is The layer contains calcium salt and / or magnesium salt and does not contain organic acid and bicarbonate, the second layer is laminated in two or more layers, and contains organic acid and contains calcium salt, magnesium salt and bicarbonate. It is a layer that does not contain, and the third layer is a sodium bicarbonate dialysis agent characterized in that it contains bicarbonate and does not contain calcium salt, magnesium salt and organic acid. This laminated preparation is filled in an airtight container that is moisture-proof in a carbon dioxide gas stream, and stored together with a desiccant.
[0007]
A preferable blending range of the components contained in the sodium bicarbonate dialysis agent of the present invention is shown as follows in terms of the composition range after preparation of the dialysate, and the pH is 7.0 to 8.0, more preferably 7.2. ~ 7.6.
Na + 120-150 mEq / l
K + 0 to 4 mEq / l
Ca ++ 1-6 mEq / l
Mg ++ 0-2 mEq / l
Cl - 90-135 mEq / l
CH 3 CO 2 - 2~ 15 mEq / l
HCO 3 - 10~ 40 mEq / l
Glucose 0-10 g / l
[0008]
In the production of the sodium bicarbonate dialysis agent of the present invention, when selecting a compound and setting the blending ratio, for example, the concentration of each component may be set based on the above, and the back calculation may be performed according to the combination of compounds capable of supplying each component.
[0009]
The electrolyte used in the present invention must be pharmacologically acceptable. For example, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, potassium acetate, calcium gluconate and the like can be mentioned.
The laminated preparation constituting the present invention can contain other components contained in blood, such as glucose, together with the electrolyte as described above.
[0010]
The laminated preparation includes a group containing a calcium salt and / or a magnesium salt and not containing an organic acid and a bicarbonate (first layer), a group containing an organic acid and not containing a calcium salt, a magnesium salt and a bicarbonate (second). Layer) and the group containing bicarbonate (calcium salt, magnesium salt and organic acid) (third layer) is important. That is, a group containing calcium salt and / or magnesium salt and not containing organic acid and bicarbonate and a group containing bicarbonate and not containing calcium salt, magnesium salt and organic acid are classified into calcium salt, magnesium salt, organic acid and bicarbonate. By laminating so as not to contact through a group selected from components other than carbonate, it is possible to prevent calcium salt and magnesium salt from reacting with bicarbonate. In addition, a group containing organic acid and not containing calcium salt, magnesium salt and bicarbonate and a group containing bicarbonate containing calcium salt, magnesium salt and organic acid other than calcium salt, magnesium salt, organic acid and bicarbonate By laminating so as not to contact through a group selected from the above components, the reaction between the bicarbonate and the organic acid can be prevented. That is, during the preparation of dialysate, it is dissolved in distilled water sequentially from the outer layer of the layered preparation, and the pH is adjusted from neutral to slightly alkaline, so that carbon dioxide is generated, and calcium salt and magnesium salt are the last. Therefore, precipitation of calcium carbonate and magnesium carbonate can be prevented. Further, the stacking order may be changed as desired, and the first layer, the second layer, and the third layer may be composed of two or more layers.
[0011]
The laminating operation of the present invention will be described below. The production method of the present invention comprises a step of sequentially laminating the core, and is carried out by a commonly used granulating and coating apparatus.
For example, the group to be used includes a calcium salt and / or a magnesium salt and does not include an organic acid and a bicarbonate, an organic acid includes a calcium salt, a group that does not include a magnesium salt and a bicarbonate, a bicarbonate that includes a calcium salt In addition, a group not containing magnesium salt and organic acid and a group selected from components other than calcium salt, magnesium salt, organic acid and bicarbonate, and each component of each group is appropriately sample mill (manufactured by Fuji Paudal) etc. Micronize with a pulverizer. Next, the core sodium chloride crystal particles are put into a centrifugal flow type coating granulator, rotated, and the fine powder is sequentially added while spraying an appropriate amount of glucose solution as a binder to obtain a spherical laminated preparation. .
[0012]
As the dosage form of the sodium bicarbonate dialysis agent of the present invention, a spherical laminated preparation is preferably laminated on the surface of the core sequentially from the first layer.
[0013]
Examples of the organic acid include acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid, malic acid and the like, and citric acid is particularly preferable. The amount of acid used is preferably added so that the pH of the dialysate is in the range of 7.0 to 8.0. A more preferable range is pH 7.2 to 7.6. These organic acids can be used alone or in combination of two or more.
[0014]
The binder used in the method for producing a layered preparation of the present invention is safe because glucose in the component is used, and since the binding force is strong, it is possible to obtain a layered preparation that is high in strength and hardly powdered. Glucose is appropriately dissolved in a solvent and used, but a preferable concentration is 0.5 to 55 W / W%. The solvent is not particularly limited as long as it is used for formulation and dissolves glucose, but is preferably water or a mixed solvent of water and ethanol.
[0015]
The material used in the storage container for the sodium bicarbonate dialysis agent of the present invention is not particularly limited as long as it is substantially moisture-proof and gas-impermeable, but for example, polyethylene, polypropylene, polyvinyl chloride, or aluminum A laminate film in which such metal foil, nylon, cellophane, etc. are appropriately laminated in two or multiple layers can be mentioned.
[0016]
It is advantageous to seal the airtight container in the packaging form as described above together with a desiccant in a carbon dioxide gas stream because the stability can be further improved. As the desiccant, silica gel, calcium chloride, calcium carbonate and the like are used.
[0017]
[Action]
Since the baking soda dialysis agent thus obtained is laminated so that the organic acid and the bicarbonate are not in contact with each other, reaction between components can be prevented. Also, when preparing the dialysate, it is dissolved from bicarbonate in order without adjusting pH, the pH of the solution is adjusted from neutral to slightly alkaline, and finally calcium salt and magnesium salt are dissolved. Therefore, no carbonate precipitate is formed.
[0018]
【Example】
EXAMPLES Hereinafter, although this invention is demonstrated further in detail based on an Example and a test example, this invention is not limited to these Examples.
[Example 1]
Magnesium chloride 17.9g, calcium chloride 38.7g and potassium chloride 26.1g were stirred with a universal stirrer (Shinagawa Kogyo, SD-02 type), and pulverized with a sample mill (Fuji Paudal, pulverizer KIIW-1). One layer of fine powder was obtained. Similarly, 35 g of citric acid and 105 g of sodium chloride were mixed and pulverized to obtain a fine powder of the second layer (inner layer). Glucose 91.0 g, sodium acetate 85.9 g and sodium chloride 100.9 g were subjected to the same operation as above to obtain a fine powder of the second layer (intermediate layer). As the second layer (outer layer), 157.5 g of sodium chloride was pulverized to obtain a fine powder. Further, 441 g of sodium bicarbonate was pulverized as a third layer to obtain a fine powder. Next, 700 g of sodium chloride having a particle diameter of 350 to 500 μm is placed in a centrifugal fluidized granulating coating apparatus (Freund Sangyo Co., Ltd., CF-360S type), rotated (rotation speed 200 rpm), and sprayed with the glucose solution, the first layer, Fine powders were added in the order of the second layer (inner layer), the second layer (intermediate layer), the second layer (outer layer) and the third layer to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.
[0019]
[Example 2]
Magnesium chloride 17.9 g, calcium chloride 38.7 g and potassium chloride 26.1 g were stirred with a universal stirrer and pulverized with a sample mill to obtain a fine powder of the first layer. Similarly, 35 g of citric acid and 105 g of sodium chloride were mixed and pulverized to obtain a fine powder of the second layer (inner layer). The same operation as described above was performed on 91.0 g of glucose and 100.9 g of sodium chloride to obtain a fine powder of the second layer (intermediate layer). As the second layer (outer layer), 85.9 g of sodium acetate and 157.5 g of sodium chloride were pulverized to obtain a fine powder. Further, 441 g of sodium bicarbonate was pulverized as a third layer to obtain a fine powder. Next, 700 g of sodium chloride having a particle diameter of 350 to 500 μm is placed in a centrifugal fluidized granulating coating apparatus (Freund Sangyo Co., Ltd., CF-360S type), rotated (rotation speed 200 rpm), and sprayed with the glucose solution, the first layer, Fine powders were added in the order of the second layer (inner layer), the second layer (intermediate layer), the second layer (outer layer) and the third layer to obtain a spherical laminated preparation. The obtained layered preparation was dried by a conventional method to obtain the intended dialysis agent.
[0020]
Example 3
Put 700g of sodium chloride with a particle size of 350-500μm in a tumbling fluidized granulation dryer (multiplex, MP-01 type, manufactured by Paulex) and refine 17.9g of magnesium chloride, 38.7g of calcium chloride and 26.1g of potassium chloride. The liquid of the first layer dissolved in 193 g of water was coated. Next, a second layer (inner layer) solution in which 35 g of citric acid and 105 g of sodium chloride were dissolved in 326.7 g of purified water was coated, and 148.75 g of glucose, 85.9 g of sodium acetate, and 100.9 g of sodium chloride were sequentially added to semen water. The liquid of the second layer (intermediate layer) dissolved in 4139.1 g and the liquid of the second layer (outer layer) prepared by dissolving 157.5 g of sodium chloride in 472.5 g of water were coated. Third, 700 g of the above-mentioned granulated product was put into a centrifugal fluidized granulating coating device (Freund Sangyo Co., Ltd., CF-360S type), rotated (rotation speed: 200 rpm), and ground with a sample mill while spraying a glucose solution. 214 g of fine powder of sodium hydrogen carbonate in the layer was added to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.
[0021]
Example 4
Magnesium chloride 17.9g, calcium chloride 38.7g and potassium chloride 26.1g were stirred with a universal stirrer (Shinagawa Kogyo, SD-02 type), and pulverized with a sample mill (Fuji Paudal, pulverizer KIIW-1). One layer of fine powder was obtained. Similarly, 35 g of citric acid and 105 g of sodium chloride were mixed and pulverized to obtain a fine powder of the second layer (inner layer). Glucose 91.0 g, sodium acetate 85.9 g and sodium chloride 258.4 g were treated in the same manner as above to obtain a fine powder of the second layer (outer layer). Further, 441 g of sodium bicarbonate was pulverized as a third layer to obtain a fine powder. Next, 700 g of sodium chloride having a particle diameter of 350 to 500 μm is placed in a centrifugal fluidized granulating coating apparatus (Freund Sangyo Co., Ltd., CF-360S type), rotated (rotation speed 200 rpm), and sprayed with the glucose solution, the first layer, Fine powder was added in the order of the second layer (inner layer), the second layer (outer layer), and the third layer to obtain a spherical laminated preparation. The obtained laminated preparation was dried by a conventional method to obtain the intended dialysis agent.
[0022]
[Test Example 1] Stability Test The dialysis agent obtained in Example 1 was 1) no desiccant and carbon dioxide replacement, 2) silica gel was stored as the desiccant, 3) the container was replaced with carbon dioxide, and 4) dried. Silica gel is stored as an agent, and the container is placed in a glass bottle under four conditions of carbon dioxide replacement, sealed and stored at 40 ° C., then color difference (ΔE), presence / absence of aggregation, concentration of bicarbonate ion after dissolution And the pH was measured.
The color difference was measured using a color difference meter (manufactured by Nippon Denshoku Industries Co., Ltd., Σ80 type) using a standard white plate as a control. For bicarbonate ion and pH, dissolve 10.76 g of sample in purified water to 1000 ml, and use ion chromatography (Yokogawa Electric, IC-500S type) and pH meter (Horiba, F-16 type), respectively. It was measured.
The results are shown in Table 1.
[0023]
[Table 1]
[0024]
From the above results, it was revealed that coloring was suppressed by storing together with silica gel, and that the hydrogen carbonate ion content was stably maintained by substitution with carbon dioxide gas. Moreover, in the case of dissolution, all dissolved quickly within several minutes.
[0025]
【The invention's effect】
Since the baking soda dialysis agent of the present invention is laminated in multiple layers as described above, it is excellent in long-term stability. Moreover, since all necessary components are contained in one agent, handling is easy.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16994594A JP3647898B2 (en) | 1994-06-28 | 1994-06-28 | Sodium bicarbonate dialysis agent and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16994594A JP3647898B2 (en) | 1994-06-28 | 1994-06-28 | Sodium bicarbonate dialysis agent and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08169836A JPH08169836A (en) | 1996-07-02 |
| JP3647898B2 true JP3647898B2 (en) | 2005-05-18 |
Family
ID=15895802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16994594A Expired - Fee Related JP3647898B2 (en) | 1994-06-28 | 1994-06-28 | Sodium bicarbonate dialysis agent and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3647898B2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11343230A (en) * | 1998-05-27 | 1999-12-14 | Nissho Corp | Agent for solid sodium bicarbonate dialysis |
| US6770148B1 (en) | 1998-12-04 | 2004-08-03 | Baxter International Inc. | Peritoneal dialysis solution containing modified icodextrins |
| US7186420B2 (en) | 1999-04-26 | 2007-03-06 | Edwards Lifesciences Corporation | Multi-part substitution infusion fluids and matching anticoagulants |
| US8105258B2 (en) | 1999-04-26 | 2012-01-31 | Baxter International Inc. | Citrate anticoagulation system for extracorporeal blood treatments |
| DE60009791T2 (en) | 1999-06-07 | 2004-08-19 | Nipro Corp. | Solid pharmaceutical preparation for dialysis and process for its manufacture |
| US7544301B2 (en) * | 2004-08-19 | 2009-06-09 | Hhd Llc | Citrate-based dialysate chemical formulations |
| JP2008007524A (en) * | 2007-09-21 | 2008-01-17 | Nipro Corp | Solid sodium bicarbonate dialysis agent |
| JP2008007523A (en) * | 2007-09-21 | 2008-01-17 | Nipro Corp | Solid sodium bicarbonate dialysis agent |
| JP5469482B2 (en) * | 2010-03-01 | 2014-04-16 | ニプロ株式会社 | Solid baking soda dialysis agent |
| JP5376480B1 (en) * | 2012-10-10 | 2013-12-25 | 富田製薬株式会社 | A dialysis agent containing acetic acid and acetate, and two-agent dialysis agent using the same |
| CN109432123B (en) * | 2018-11-23 | 2021-07-20 | 济南康和医药科技有限公司 | Compound electrolyte glucose injection and preparation method thereof |
| JP7450957B2 (en) * | 2022-04-08 | 2024-03-18 | 富田製薬株式会社 | Agent A for hemodialysis and agent for hemodialysis |
| WO2025144780A1 (en) | 2023-12-27 | 2025-07-03 | Baxter International Inc. | Solid pharmaceutical preparation for peritoneal dialysis and process for producing the same |
-
1994
- 1994-06-28 JP JP16994594A patent/JP3647898B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08169836A (en) | 1996-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6489301B1 (en) | Solid pharmaceutical preparation for dialysis and a process for producing the same | |
| EP0602014B1 (en) | Preparation for blood dialysis and method for production thereof | |
| JP3647898B2 (en) | Sodium bicarbonate dialysis agent and method for producing the same | |
| EP0177614B1 (en) | Process for producing mixed electrolyte powder for use in bicarbonate dialysis | |
| EP1192961B1 (en) | Solid preparation for dialysis and process for producing the same | |
| EP0417478B2 (en) | Sodium bicarbonate containing mixture for producing a dialysis solution | |
| JP3619921B2 (en) | Bicarbonate solid dialysis agent | |
| JP3530235B2 (en) | Hemodialysis agent | |
| EP2151247A1 (en) | Solid dialysis preparation | |
| JP6366214B1 (en) | Agent A for hemodialysis | |
| JP3384841B2 (en) | Baking soda dialysis agent | |
| JP3398184B2 (en) | Dialysis agent | |
| JP2749375B2 (en) | Preparation for hemodialysis and method for producing the same | |
| EP1714657A1 (en) | Solid formulation for dialysis and process for producing the same | |
| JP3415291B2 (en) | Bicarbonate dialysis agent | |
| EP1192960B1 (en) | Solid preparation for dialysis and process for producing the same | |
| JPH04257522A (en) | Dialyzing agent for sodium bicarbonate | |
| JP2809971B2 (en) | Hemodialysis preparation | |
| JPH10259133A (en) | Granular dialysis agent and method for producing the same | |
| JPH11114054A (en) | Solid dialysis agent | |
| JPH0338527A (en) | Preparation for blood dialysis and its production | |
| EP1086700B1 (en) | A solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same | |
| JP3951284B2 (en) | Solid preparation for dialysis and method for producing the same | |
| JP5028122B2 (en) | Single-agent dialysis solid preparation and method for producing the same | |
| JP2001327597A (en) | Pharmaceutical preparation for solid sodium carbonate dialysis and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050210 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080218 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090218 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090218 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100218 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100218 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110218 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110218 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |